Clinically, approximately 90% of diabetes patients have been diagnosed with T2DM, which is characterized by a reduction in insulin sensitivity and dysfunction of β-cells with hyperglycemia and dyslipidemia (Zhang et al., 2016; Punthakee et al., 2018). This evidence concerns the gene INS and metabolic syndrome.